Phase 2 Pancreatic Cancer Trial, Recruiting NCT05116072 Sponsor: University Hospital, Lille Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Phase 2 Pancreatic Cancer Trial, Recruiting

NCT05116072
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years of age or older
  • You have been diagnosed with a specific type of cancer in the head of the pancreas (pancreatic adenocarcinoma, duodenal adenocarcinoma, ampullary adenocarcinoma, or a cyst-related cancer called IPMN with adenocarcinoma), confirmed by a specialist scan and tissue sample
  • A team of medical experts has agreed that surgery to remove the tumour is a suitable option for you
  • Before surgery, you show 2 or more signs that suggest a higher risk of a specific post-surgery complication (such as being male, having a BMI of 30 or above, having a small pancreatic duct, having excess abdominal fat, or having low muscle mass) — and this higher risk is also confirmed during the operation itself
  • If you are a woman who could become pregnant, you have had a recent menstrual period and a negative pregnancy test, and you agree to monthly pregnancy testing during the chemotherapy part of the trial
  • If you are a woman who could become pregnant, or a male participant whose partner could become pregnant, you agree to use highly effective contraception during chemotherapy and for a set period afterwards (6 months for women, 1 month for men)
  • You are covered by a health insurance system
  • You have read and signed a consent form agreeing to take part in the study

Who may not be able to join:

  • You have a specific type of diabetes identified by a pre-surgery blood test showing very low insulin production (confirm with trial site)
  • You have a known or strongly suspected inherited genetic condition linked to pancreatic cancer risk (such as familial pancreatic cancer, Lynch syndrome, Peutz-Jeghers syndrome, Li-Fraumeni syndrome, or several other hereditary conditions)
  • Your cancer has been found in more than one area of the pancreas before surgery
  • Your overall health or other medical conditions make major abdominal surgery unsuitable
  • There is a medical reason why you cannot receive a specific procedure involving transplanting insulin-producing cells into a vein in your liver (confirm with trial site)
  • You are currently receiving, or are planned to receive, chemotherapy before surgery (neoadjuvant chemotherapy)
  • Your cancer has already spread outside the pancreas, as identified before or during surgery
  • You would need complex reconstruction of major blood vessels as part of your surgery
  • There are signs of inflammation of the pancreas linked to a bile drain that could interfere with the cell isolation process (confirm with trial site)
  • You have a known infection or positive blood test for HIV, Hepatitis B or C, HTLV, or syphilis
  • You currently have an active COVID-19 infection (positive PCR test) — in this case, the procedure would need to be rescheduled at least 30 days later
  • You are pregnant or currently breastfeeding
  • You have a complete deficiency of an enzyme called dihydropyrimidine dehydrogenase, which affects how the body processes certain chemotherapy drugs
  • You are unable to understand the purpose, benefits, and risks of the study, or cannot give written consent
  • You are unable to follow the full schedule of the trial
  • You are not covered by a health insurance system
  • You are currently detained, receiving certain types of psychiatric care, living in a care institution, or are in an emergency situation

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: François PATTOU, MD,PhD, University Hospital, Lille

Phone: 0320445962

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
20 February 2022
Est. completion
20 February 2028

Where this trial is recruiting

🇫🇷 France

Primary endpoints

the rate of patients who have completed the chemotherapy planned

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov